[Edaily Reporter Kim Ji-woo ] SPC SAMLIP(005610)has set a goal of achieving consolidated revenue of 4.5 trillion won and an operating profit margin of 4.4% by 2030. The company plans to enhance shareholder value by expanding its global operations and improving the profitability of its bakery and food businesses, while increasing its medium- to long-term dividend payout ratio to 30%.
SAMLIP logo. (Photo courtesy of SAMLIP) SAMLIP announced this mid- to long-term management strategy in a regulatory filing on the 29th. The company set its standalone performance targets for 2030 at 2.1 trillion won in revenue and an operating profit margin of 8%.
The company identified the expansion of global sales, the stabilization of the bakery business, and the improvement of its profitability as key strategies for achieving these goals. For the food business, the company plans to restructure its portfolio to focus on sectors with high growth potential and profitability. Establishing a culture of safety was also included in the mid-to-long-term core strategies.
The company also plans to expand shareholder returns. SAMLIP aims to increase dividends with a target medium- to long-term dividend payout ratio of 30% and plans to enhance shareholder value through responsible management and transparent communication.
SAMLIP is scheduled to hold an investor relations (IR) briefing led by its CEO this afternoon to share its mid- to long-term performance targets and management strategies with domestic and international investors and the media.
A serious accident resulting in the death of a worker occurred at a new apartment construction site operated by #Hyundai Engineering, a major subsidiary of HyundaiEngineering&Construction(000720).Acco…
Amid unfavorable external factors—such as a decline in home sales volume in the third quarter due to high interest rates and loan restrictions, as well as rising prices of raw materials and supplies s…
AprilBio Co.,Ltd.(397030)is set to pursue technology exports at the preclinical stage next year, spearheaded by three new drug candidates: bispecific antibodies, short interfering RNA (siRNA), and ant…